The tallest steel-framed building ever tested on an earthquake simulator started moving slowly, swaying and twisting. The ...

Students and professors will research vaccines, cancer treatments and medical applications of artificial intelligence in the ...

A test developed by a Madison company to better track cancer DNA in the blood stream will now be covered by Medicare.

Learn about the $7.5 million project transforming the surface lot into a vibrant green space at The Science Museum of ...

The Department of Housing and Urban Development had previously announced its intention to sell its current headquarters, ...

Exact Sciences Corporation’s (NASDAQ:EXAS) first quarter revenue experienced 11% rise on reported and core basis exceeding the mid pint of guidance over $19 million.

Building upon decades of research, Exact Sciences intends to harness the additive sensitivity of multiple biomarker classes to detect more cancers in earlier stages.

Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis.

Building on the success of the Cologuard ® and Oncotype ® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis.

Building on the success of the Cologuard ® and Oncotype ® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis.

“The Exact Sciences team is off to a good start in 2025, building on the momentum we created in the fourth quarter,” said Kevin Conroy, chairman and CEO of Exact Sciences.